US89532E2081 - Common Stock
Trevena (TRVN) files prospectus for the resale of 2.78M shares of common stock by selling stockholders.
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on...
Trevena (TRVN) announces agreements for the sale of shares and warrants, expected to generate $4M in gross proceeds.
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the...
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked...
CHESTERBROOK, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
Trevena (TRVN) files SEC prospectus to raise $200M through offering common stock, preferred stock, debt securities, and warrants.
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS...
Company to host a Conference Call & Webcast at 8:00 a.m. ET...
TRV045 was well tolerated with results generally consistent with prior first-in-human study No drug-related adverse events and no serious adverse events...
Continuous respiratory monitoring data for ~200 complex surgical patients treated with IV OLINVYK at Cleveland Clinic and Wake Forest Baptist Health in the...
Trevena (TRVN) has received a $15 million tranche under its non-dilutive ex-U.S
$15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena’s partner in China ...
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045...
CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of...
$3 million milestone payment for Chinese approval of OLINVYK® (oliceridine) injection The Company also eligible to receive $15 million non-dilutive...
Nasdaq has notified Trevena (TRVN) that the company has regained compliance with the minimum bid price requirement under Nasdaq listing rule.The Company maintained a minimum closing...
CHESTERBROOK, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...
OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company’s China partner Jiangsu Nhwa Pharmaceutical Company...